Vaccination work is going on as a campaign to overcome the increasing outbreak of covid-19. In a phased manner for vaccination, the priority was given to health workers, then to older people. After this, the youth was vaccinated and now Indonesia has taken the initiative of vaccines for children.
Vaccination target of 13 lakh children
The country's health ministry has launched a massive COVID-19 vaccination for children in the age group of 12 to 17 years. About a hundred students were administered the first dose of the vaccine during a vaccination program at a public high school in Central Jakarta on Thursday, Xinhua news agency reported. The city administration has set a target of immunization of around 13 lakh children, who will be vaccinated with the help of schools and health centers. After the country's National Agency of Drug and Food Control issued permission for emergency use on June 20 last month, now children aged 12 to 17 years will be given the Sinovac vaccine.
Vaccination continues under the campaign
The first dose of the vaccine has been administered to about 30.48 lakh people in the country till July 1. At the same time, about 13.67 lakh others have received their second dose of vaccine. Indonesia has set a target of reaching the country's 1815 million people by March 2022, which is about 70 percent of the country's population. According to the latest released data, about 22 lakh 3 thousand 108 cases of corona have been reported in the country so far, while the death toll of the infection is about 58 thousand 995.
Health workers in Indonesia begin vaccination in January
Significantly, in Indonesia, vaccination of health workers on a priority basis started in January. In a statement issued by the Indonesian Medical Association, it was said that everyone is being given the Kovid-19 vaccine developed by the Chinese biopharmaceutical company Sinovac. Now Sinovac itself will also be used to vaccinate children. The World Health Organization approved the emergency use of Sinovac this month. It was also told that the test has shown that the vaccine has prevented the infection from reaching serious conditions in about 51 percent of the people.